Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2022 - 11 - 10 save search
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-10 (Crawled : 23:00) - globenewswire.com
CRSP | News M | $56.46 1.44% 1.42% 1.2M
|
Health Technology
|
| O: -1.01%
H: 14.93%
C: 11.47%
crispr immunotherapy meeting therapeutics cancer
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Published: 2022-11-10 (Crawled : 21:00) - globenewswire.com
GTBP | $3.69 -2.38% -2.44% 11K
|
Manufacturing
|
| O: 0.24%
H: 4.53%
C: 1.67%
biopharma immunotherapy meeting cancer
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
Published: 2022-11-10 (Crawled : 18:00) - biospace.com/
NRIX 6 d | $14.125 4.01% 3.86% 690K
|
Health Technology
|
| O: 5.25%
H: 9.9%
C: 8.71%
nx-1607 immunotherapy meeting cancer
BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
Published: 2022-11-10 (Crawled : 18:00) - biospace.com/
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: 5.92%
H: 2.71%
C: -0.51%
treatment immunotherapy meeting breast positive cancer
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 18:00) - globenewswire.com
IOVA M | $11.86 4.77% 4.55% 3.9M
|
Health Technology
|
| O: 6.12%
H: 4.99%
C: 4.21%
melanoma immunotherapy meeting cancer
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
Published: 2022-11-10 (Crawled : 17:00) - biospace.com/
HOWL | $6.41 5.26% 4.99% 390K
|
Professional, Scientific, and T...
|
| O: 6.08%
H: 0.21%
C: -2.76%
wtx-330 preclinical immunotherapy meeting therapeutics il-12 cancer
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 16:00) - biospace.com/
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
|
| O: 2.23%
H: 7.24%
C: 6.28%
nktr-288 preclinical immunotherapy meeting therapeutics cancer
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Published: 2022-11-10 (Crawled : 15:20) - biospace.com/
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: 2.04%
H: 9.65%
C: 5.78%
preclinical immunotherapy meeting cancer
Seagen to Highlight New Research from its Diverse Pipeline of Targeted Cancer Therapy Candidates at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 15:00) - biospace.com/
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.69%
H: 0.1%
C: -3.37%
research immunotherapy meeting therapy cancer
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
Published: 2022-11-10 (Crawled : 14:20) - biospace.com/
SQZ | $0.435 0.0% 30M
|
Health Technology
|
| O: 9.84%
H: 1.43%
C: -3.23%
ander-001 squeeze preclinical sqz immunotherapy meeting mrna trial cancer
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort
Published: 2022-11-10 (Crawled : 14:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 5.06%
H: 6.42%
C: 4.81%
biotech meeting response cancer pancreatic
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:20) - allogene.com
ALLO | $3.365 -1.03% -1.04% 1.6M
|
Health Technology
|
| O: 4.79%
H: 5.66%
C: 3.92%
immunotherapy meeting control therapeutics cancer
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:20) - globenewswire.com
SCPS | $0.1682
|
|
| O: 3.29%
H: 12.99%
C: 10.73%
immunotherapy meeting cancer
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2022-11-10 (Crawled : 14:00) - investors.senseibio.com
SNSE | $1.01 8.5% 7.83% 85K
|
|
| O: 2.92%
H: 7.09%
C: 6.38%
preclinical immunotherapy meeting cancer
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 14:00) - ir.vaccinex.com
VCNX | $4.94 -2.76% 7.4K
|
Health Technology
|
| O: 3.0%
H: 6.78%
C: 1.69%
trials immunotherapy meeting pepinemab cancer
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th
Published: 2022-11-10 (Crawled : 14:00) - investors.phiopharma.com
PHIO | News | $0.6709 -19.16% -23.7% 640K
|
Health Technology
|
| O: 6.63%
H: 3.0%
C: -12.9%
pharmaceuticals immunotherapy meeting cancer study
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
Published: 2022-11-10 (Crawled : 13:20) - globenewswire.com
PVCT 4 | $0.1948 -15.0% 63K
|
Manufacturing
|
| O: -2.57%
H: 3.77%
C: 1.89%
pv-10 melanoma immunotherapy cancer
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2022-11-10 (Crawled : 09:00) - biospace.com/
NBTX | $5.79 1.05% 1.04% 27K
|
Manufacturing
| Email alert
Add to watchlist
immunotherapy meeting potential cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.